- Home
- DXR vs CALC Comparison
DXR vs CALC Comparison
Compare DXR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CALC
- Stock Information
- Founded
- DXR 1970
- CALC 2011
- Country
- DXR United States
- CALC United States
- Employees
- DXR N/A
- CALC N/A
- Industry
- DXR Medical/Dental Instruments
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- CALC Health Care
- Exchange
- DXR Nasdaq
- CALC Nasdaq
- Market Cap
- DXR 40.3M
- CALC 36.0M
- IPO Year
- DXR N/A
- CALC N/A
- Fundamental
- Price
- DXR $8.08
- CALC $1.84
- Analyst Decision
- DXR Strong Buy
- CALC Strong Buy
- Analyst Count
- DXR 1
- CALC 4
- Target Price
- DXR $25.00
- CALC $17.25
- AVG Volume (30 Days)
- DXR 8.9K
- CALC 74.5K
- Earning Date
- DXR 01-01-0001
- CALC 03-27-2025
- Dividend Yield
- DXR N/A
- CALC N/A
- EPS Growth
- DXR 86.16
- CALC N/A
- EPS
- DXR 0.11
- CALC N/A
- Revenue
- DXR $119,714.00
- CALC N/A
- Revenue This Year
- DXR N/A
- CALC N/A
- Revenue Next Year
- DXR N/A
- CALC N/A
- P/E Ratio
- DXR $73.78
- CALC N/A
- Revenue Growth
- DXR N/A
- CALC N/A
- 52 Week Low
- DXR $6.55
- CALC $1.83
- 52 Week High
- DXR $10.00
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- DXR 55.84
- CALC 42.94
- Support Level
- DXR $8.02
- CALC $1.81
- Resistance Level
- DXR $8.50
- CALC $2.21
- Average True Range (ATR)
- DXR 0.42
- CALC 0.15
- MACD
- DXR -0.01
- CALC 0.01
- Stochastic Oscillator
- DXR 35.56
- CALC 47.10
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.